Pluri (PLUR) congratulates Mesoblast and its Chief Executive Officer, Silviu Itescu, on the U.S. Food and Drug Administration approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease. This landmark achievement marks a moment in the advancement of regenerative medicine and highlights the growing clinical and regulatory recognition of MSC therapies’ transformative potential. “This milestone is not just a triumph for Mesoblast, but for the entire field of cellular medicine,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “Silviu and the team at Mesoblast have opened a new chapter in harnessing MSC therapies to treat devastating conditions like SR-aGVHD.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PLUR:
- Pluri assesses readiness to mass produce PLX-R18
- BrainStorm enters MOU with Pluri to support NurOwn trial
- Pluri collaborates with Bar-Ilan University to advance cancer immunotherapy
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
